Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg-Hessen, and University Hospital Ulm, Ulm, Germany.
Institute of Transfusion Medicine, University of Ulm, Ulm, Germany.
Front Immunol. 2021 Jan 25;11:614976. doi: 10.3389/fimmu.2020.614976. eCollection 2020.
T-cell epitope matching according to the TCE3 algorithm classifies HLA-DPB1 mismatches in permissive and non-permissive. This classification has been shown to be predictive for mortality and acute GvHD (aGvHD) events in large international cohorts. We retrospectively genotyped HLA-DPB1 in 3523 patients transplanted in Germany between 2000 and 2014 and in their unrelated donors using an Illumina amplicon-NGS based assay. Aim of the study was to evaluate DP-compatibility beyond the established TCE3 algorithm by assessing the combined effect of several DP-mismatch parameters on post-transplant outcome. We implemented an extended DP-mismatch assessment model where TCE3, DP allotype expression with respect to rs9277534, mismatch vector and number of mismatches were conjointly taken into consideration. In this model, non-permissive HLA-DPB1 mismatches showed significantly increased aGvHD risk if they were accompanied by two HLA-DPB1 mismatches in GvH direction (HR: 1.46) or one mismatched highly expressed patient allotype (HR: 1.53). As previously reported, non-permissive HLA-DPB1 mismatches associated with a significantly higher risk of aGvHD and non-relapse mortality (HR 1.36 and 1.21, respectively), which in turn translated into worse GvHD and relapse free survival (HR 1.13). Effects on GvL and GvHD appeared strongest in GvH-directed non-permissive mismatches. Our study results support the consideration of additional HLA-DPB1 mismatch parameters along with the established TCE3 matching algorithm for refinement of future donor selection. In particular, our findings suggest that DP non-permissiveness associated with two HLA-DPB1 mismatches or at least on highly expressed mismatched patient allotype should be avoided.
根据 TCE3 算法进行 T 细胞表位匹配,将 HLA-DPB1 错配分为允许性和非允许性。这一分类在大型国际队列中已被证明对死亡率和急性移植物抗宿主病(aGvHD)事件具有预测性。我们回顾性地对 2000 年至 2014 年在德国接受移植的 3523 名患者及其无关供者进行了 HLA-DPB1 基因分型,使用了基于 Illumina 扩增子-NGS 的检测方法。该研究的目的是通过评估几个 DP 错配参数对移植后结果的综合影响,评估 TCE3 算法之外的 DP 相容性。我们实施了一个扩展的 DP 错配评估模型,其中 TCE3、与 rs9277534 相关的 DP 同种异型表达、错配向量和错配数量被联合考虑。在这个模型中,如果非允许性 HLA-DPB1 错配伴随着两个移植物抗宿主病方向的 HLA-DPB1 错配(HR:1.46)或一个错配的高度表达患者同种异型(HR:1.53),则会显著增加 aGvHD 风险。与之前的报道一致,非允许性 HLA-DPB1 错配与 aGvHD 和非复发死亡率显著相关(HR 分别为 1.36 和 1.21),这反过来又导致 aGvHD 和无复发生存(HR 分别为 1.13)恶化。在移植物抗宿主病方向的非允许性错配中,对 GvL 和 GvHD 的影响最为明显。我们的研究结果支持在未来的供者选择中,考虑额外的 HLA-DPB1 错配参数与既定的 TCE3 匹配算法相结合,以进一步细化。特别是,我们的研究结果表明,应避免与两个 HLA-DPB1 错配或至少与高度表达的错配患者同种异型相关的 DP 非允许性。